日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Phase 1 Dose-Escalation, Food Effect, and Drug-Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR-1505, in Healthy Volunteers

一项评估 MALT1 抑制剂 SGR-1505 在健康志愿者中的安全性、耐受性、药代动力学和药效学的 1 期剂量递增、食物影响和药物相互作用研究

Gupta, Vipul K; Yoo, Brian; Weiss, Daniel; Basile, Frank G; Schuck, Edgar; Rubino, Christopher M; Zhang, Sen; Maxwell, Stephen E; Zheng, Wenxin; Tan, Joanne B L; Stenehjem, David; Watkins, Paul B; Dugan, Margaret; Yin, Wu; Wright, D Hamish; Akinsanya, Karen; Lickliter, Jason

A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteers

一项随机、双盲、1期、单剂量和多剂量安慰剂对照研究,旨在评估吸入式抗体疗法IN-006在健康志愿者中治疗COVID-19的安全性和药代动力学。

Moench, Thomas R; Botta, Lakshmi; Farrer, Brian; Lickliter, Jason D; Kang, Hyunah; Park, Yoona; Kim, Cheolmin; Hoke, Marshall; Brennan, Miles; McSweeney, Morgan D; Richardson, Zachary; Whelan, John B; Cho, Jong Moon; Lee, Soo Young; Faurot, Frances; Hutchins, Jeff; Lai, Samuel K

First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus

首次人体试验评估AT-752(一种对登革病毒具有泛血清型活性的新型核苷酸前药)的安全性和药代动力学

Zhou, Xiao-Jian; Lickliter, Jason; Montrond, Maureen; Ishak, Laura; Pietropaolo, Keith; James, Dayle; Belanger, Bruce; Horga, Arantxa; Hammond, Janet

A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults

一项关于增强型双重 BAFF/APRIL 拮抗剂 povetacicept 在健康成人中的安全性、药代动力学和药效学的首次人体随机研究

Rupert Davies, Stanford L Peng, Jason Lickliter, Kristi McLendon, Amanda Enstrom, Allison G Chunyk, Lori Blanchfield, NingXin Wang, Tiffany Blair, Heather M Thomas, Alina Smith, Stacey R Dillon

Erratum for Lickliter et al., "Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects"

勘误表:Lickliter 等人,“静脉注射 β-内酰胺酶抑制剂 Durlobactam 在健康受试者中的安全性、药代动力学和药物相互作用潜力”

Lickliter, Jason D; Lawrence, Kenneth; O'Donnell, John; Isaacs, Robin

Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme

十二氟戊烷乳剂作为多形性胶质母细胞瘤的放射增敏剂

Lickliter, Jason D; Ruben, Jeremy; Kichenadasse, Ganessan; Jennens, Ross; Gzell, Cecelia; Mason, Ralph P; Zhou, Heling; Becker, Jennifer; Unger, Evan; Stea, Baldassarre

A phase I randomized, double-blinded, placebo-controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects.

一项 I 期随机、双盲、安慰剂对照研究,评估 RIPK1 抑制剂 GFH312 在健康受试者中的安全性和药代动力学

Lickliter Jason, Wang Shuang, Zhang Wenxin, Zhu Huaqiang, Wang Jing, Zhao Congqiao, Shen Haige, Wang Yu

A Cathepsin-Targeted Quenched Activity-Based Probe Facilitates Enhanced Detection of Human Tumors during Resection

一种靶向组织蛋白酶的淬灭活性探针可提高切除过程中对人类肿瘤的检测率

Kennedy, Gregory T; Holt, David E; Azari, Feredun S; Bernstein, Elizabeth; Nadeem, Bilal; Chang, Ashley; Sullivan, Neil T; Segil, Alix; Desphande, Charuhas; Bensen, Eric; Santini, John T; Kucharczuk, John C; Delikatny, Edward J; Bogyo, Matthew; Egan, A J Matthew; Bradley, Charles W; Eruslanov, Evgeniy; Lickliter, Jason D; Wright, Gavin; Singhal, Sunil

A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors

GSK2849330(一种抗HER3单克隆抗体)在HER3表达实体瘤中的I期首次人体研究

Gan, Hui K; Millward, Michael; Jalving, Mathilde; Garrido-Laguna, Ignacio; Lickliter, Jason D; Schellens, Jan H M; Lolkema, Martijn P; Van Herpen, Carla L M; Hug, Bruce; Tang, Lihua; O'Connor-Semmes, Robin; Gagnon, Robert; Ellis, Catherine; Ganji, Gopinath; Matheny, Christopher; Drilon, Alexander

Opinion: Advancing Embodiment Research From a Developmental Point of View

观点:从发展心理学的角度推进具身认知研究

Lickliter, Robert